Braidwell LP Increases Holdings in TransMedics Group, Inc. $TMDX

Braidwell LP lifted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 85.1% during the second quarter, HoldingsChannel reports. The firm owned 609,715 shares of the company’s stock after purchasing an additional 280,324 shares during the quarter. TransMedics Group accounts for about 1.5% of Braidwell LP’s investment portfolio, making the stock its 25th biggest holding. Braidwell LP’s holdings in TransMedics Group were worth $40,497,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in TMDX. Silvant Capital Management LLC purchased a new stake in TransMedics Group during the second quarter worth about $26,000. Harvest Fund Management Co. Ltd purchased a new position in TransMedics Group in the third quarter valued at about $29,000. North Star Investment Management Corp. bought a new position in shares of TransMedics Group during the 1st quarter valued at approximately $30,000. Ascentis Independent Advisors purchased a new stake in shares of TransMedics Group during the 1st quarter worth approximately $30,000. Finally, Allworth Financial LP increased its stake in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Insider Activity

In other news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on TMDX shares. Oppenheimer cut shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Weiss Ratings raised TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday. TD Cowen restated a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a research note on Wednesday, July 1st. Needham & Company LLC dropped their price target on TransMedics Group from $142.00 to $106.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. Finally, Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $124.18.

TransMedics Group Trading Up 2.5%

TransMedics Group stock opened at $84.29 on Thursday. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The stock has a market cap of $2.91 billion, a P/E ratio of 21.67 and a beta of 1.90. The firm’s fifty day moving average price is $79.53 and its 200-day moving average price is $92.53.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). The business had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.TransMedics Group’s quarterly revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.92 earnings per share. Equities research analysts forecast that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.